Anhui Anke BioTech Group Asset Resilience Ratio
Anhui Anke BioTech Group asset resilience ratio. Anhui Anke BioTech Group (300009) has an Asset Resilience Ratio of 21.62% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Anhui Anke BioTech Group defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Anhui Anke BioTech Group (2011–2025)
Asset resilience ratio of Anhui Anke BioTech Group from 2011 to 2025. This chart shows how Anhui Anke BioTech Group's Asset Resilience Ratio has changed over time. Read Anhui Anke BioTech Group debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Anhui Anke BioTech Group's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 300009 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.11 Billion | 21.62% |
| Total Liquid Assets | CN¥1.11 Billion | 21.62% |
Asset Resilience Insights
- Good Liquidity Position: Anhui Anke BioTech Group maintains a healthy 21.62% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Anhui Anke BioTech Group Industry Peers by Asset Resilience Ratio
Compare Anhui Anke BioTech Group's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Anhui Anke BioTech Group Asset Resilience Ratio by Year (2011–2025)
Anhui Anke BioTech Group asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Anhui Anke BioTech Group.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 21.49% | CN¥1.19 Billion ≈ $174.42 Million |
CN¥5.55 Billion ≈ $811.80 Million |
-0.80pp |
| 2024-12-31 | 22.29% | CN¥1.14 Billion ≈ $167.51 Million |
CN¥5.14 Billion ≈ $751.46 Million |
-1.86pp |
| 2023-12-31 | 24.15% | CN¥1.20 Billion ≈ $174.95 Million |
CN¥4.95 Billion ≈ $724.45 Million |
+4.35pp |
| 2022-12-31 | 19.80% | CN¥842.91 Million ≈ $123.34 Million |
CN¥4.26 Billion ≈ $622.91 Million |
-2.15pp |
| 2021-12-31 | 21.95% | CN¥805.43 Million ≈ $117.86 Million |
CN¥3.67 Billion ≈ $536.90 Million |
+3.63pp |
| 2020-12-31 | 18.32% | CN¥646.45 Million ≈ $94.60 Million |
CN¥3.53 Billion ≈ $516.39 Million |
+12.81pp |
| 2019-12-31 | 5.51% | CN¥177.85 Million ≈ $26.02 Million |
CN¥3.23 Billion ≈ $472.10 Million |
+3.34pp |
| 2017-12-31 | 2.17% | CN¥48.99 Million ≈ $7.17 Million |
CN¥2.25 Billion ≈ $329.85 Million |
-0.98pp |
| 2016-12-31 | 3.15% | CN¥62.00 Million ≈ $9.07 Million |
CN¥1.97 Billion ≈ $287.58 Million |
-5.53pp |
| 2015-12-31 | 8.68% | CN¥120.80 Million ≈ $17.68 Million |
CN¥1.39 Billion ≈ $203.54 Million |
-8.87pp |
| 2014-12-31 | 17.55% | CN¥160.71 Million ≈ $23.52 Million |
CN¥915.58 Million ≈ $133.98 Million |
-9.94pp |
| 2013-12-31 | 27.50% | CN¥206.18 Million ≈ $30.17 Million |
CN¥749.81 Million ≈ $109.72 Million |
+3.80pp |
| 2012-12-31 | 23.70% | CN¥154.72 Million ≈ $22.64 Million |
CN¥652.93 Million ≈ $95.54 Million |
-10.02pp |
| 2011-12-31 | 33.71% | CN¥203.50 Million ≈ $29.78 Million |
CN¥603.65 Million ≈ $88.33 Million |
-- |
About Anhui Anke BioTech Group
Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. It offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name… Read more